COMMUNIQUÉS West-GlobeNewswire

Reunion Neuroscience Announces Appointment of Sahil V. Kirpekar, M.D., as President and CEO
15/06/2026
Seasoned biopharma executive with extensive experience building and leading organizations and supporting therapeutic pipeline programs in psychiatry MORRISTOWN, N.J., June 15, 2026 (GLOBE NEWSWIRE) -- Reunion [...]
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
15/06/2026
Submission Supports Development of a Potential Non-Surgical Treatment for a Rare Genetic Disorder that Causes Recurrent Basal Cell Carcinomas Beginning in Childhood PHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- [...]
Immuneering Appoints Andrew Gengos as Chief Financial Officer
15/06/2026
- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Immuneering [...]
10 Barrel Brewing and Pub Beer Kick Off Pacific Northwest Summer of Soccer Celebration
15/06/2026
As global soccer fever builds, 10 Barrel Brewing and Pub Beer are bringing fans together across the Pacific Northwest with watch parties, game-day limited-edition merch and activations, sweepstakes and more BEND, Ore., [...]
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
15/06/2026
Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML 32 AML patients dosed across 40 mg, 80 mg, 120 mg and 160 mg TUS with TUS+ [...]
Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
15/06/2026
Company’s C1 platform may help address urgent need for rapid, scalable vaccine and antibody manufacturing while supporting broader commercialization across life sciences, food, nutrition and industrial markets JUPITER, [...]
Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company
15/06/2026
--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product-- --Seventh Addition to Lifecore’s Late-Stage Pipeline in Seven Months-- CHASKA, Minn., June 15, 2026 (GLOBE [...]
Le KFSH met en avant la transformation des prestataires grâce à un impact opérationnel mesurable au HLTH Europe 2026
15/06/2026
AMSTERDAM, 15 juin 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (KFSH) véhicule un message de transformation pratique des prestataires lors de sa participation au HLTH Europe 2026, [...]
Kraig Biocraft Laboratories CEO Kim Thompson Highlights Commercial Scale, Competitive Advantages, and the Future of Spider Silk in Featured Pulse 2.0 Interview
15/06/2026
Company's Founder Details Production Growth, Industry Transformation Strategy, and Expanding Commercial Opportunities for Recombinant Spider Silk ANN ARBOR, Mich., June 15, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft [...]
Novo Nordisk A/S - share repurchase programme
15/06/2026
Bagsværd, Denmark, 15 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
15/06/2026
-- Company will engage with NF1 community following recent FDA Fast Track and Rare Pediatric Disease Designations for lead NF1 treatment candidate PAS-004 – – Participants interested in meeting with Pasithea are [...]
KFSH présente un modèle d’IA appliquée au HLTH Europe 2026
15/06/2026
AMSTERDAM, 15 juin 2026 (GLOBE NEWSWIRE) -- Au HLTH Europe 2026, qui se tient à Amsterdam du 15 au 18 juin, King Faisal Specialist Hospital & Research Centre (KFSH) positionne l’IA en radiologie comme l’un des [...]
DOGECOIN CASH FILES UTILITY PATENT FOR BLOCKCHAIN INFRASTRUCTURE DESIGNED TO SUPPORT DOGECOIN APPLICATION USABILITY
15/06/2026
Mesquite, NV, June 15, 2026 (GLOBE NEWSWIRE) -- Mesquite, NV – June 15, 2026 – Dogecoin Cash, Inc. (OTC: DOGP) today announced the filing of a U.S. utility patent application with the United States Patent and Trademark [...]
ENA Respiratory Receives USPTO Notice of Allowance for Two Patents Covering TLR2 Agonists and Rhinovirus-Mediated COPD Exacerbations
15/06/2026
MELBOURNE, Australia, June 15, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral [...]
Bio Usawa Appoints Dr. Aida Habtezion, Former Chief Medical Officer at Pfizer, to its Board of Directors
15/06/2026
KIGALI, Rwanda and SAN FRANCISCO, June 15, 2026 (GLOBE NEWSWIRE) -- Bio Usawa, a biotechnology company dedicated to expanding access to high-quality biologic medicines across Africa, today announced the appointment of [...]
KFSH Presents Applied Radiology AI Model at HLTH Europe 2026
15/06/2026
AMSTERDAM, June 15, 2026 (GLOBE NEWSWIRE) -- At HLTH Europe 2026, taking place in Amsterdam from June 15 to 18, King Faisal Specialist Hospital & Research Centre (KFSH) is positioning radiology AI as one of the [...]
CancerVax Successfully Demonstrates Full Nanoparticle Delivery in Mouse Study
15/06/2026
First biodistribution study of the Company’s complete cancer targeting nanoparticle avoided many healthy organs Lehi, UT, June 15, 2026 (GLOBE NEWSWIRE) -- CancerVax Successfully Demonstrates Full Nanoparticle Delivery [...]
EURneffy 1 mg approved in the UK as the first and only needle-free adrenaline treatment for young children (aged 4 and older, 15–30 kg) at risk of anaphylaxis
15/06/2026
ALK announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for EUR neffy ® 1 mg, the first and only needle-free adrenaline treatment for anaphylaxis for [...]
Enterome presents Phase 1/2 iNHL interim data at EHA demonstrating durable OncoMimics™-induced CD8 T cell responses and clinical activity
15/06/2026
PRESS RELEASE EO2463 was well tolerated in monotherapy and in R 2 combination therapy cohorts EO2463-induced CD8 T cell expansion significantly associated with clinical response across cohorts Data support development [...]

Pages